Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
British Journal of Cancer|August 4, 2020
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumoursJuan Martin-Liberal, Antoine Hollebecque, Philippe Aftimos, et al.
The Breast Journal|December 30, 2017
Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experiencePatricia Martin-Romano, Iosune Baraibar, Jaime Espinós, et al.
The Oncologist|March 24, 2022
Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C MutationJudy Wang, Patricia Martin-Romano, Philippe Cassier, et al.
Frontiers in Immunology|November 22, 2021
Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?Patricia Martin-Romano, Julien Adam, Jean-Yves Scoazec, et al.
British Journal of Cancer|October 18, 2018
Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?Sarah Watson, Jessica Menis, Capucine Baldini, et al.
Cancer Medicine|February 20, 2020
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor typesPatricia Martin-Romano, Eduardo Castanon, Samy Ammari, et al.
Cancers|October 27, 2022
Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI ScoreMonica Pierro, Capucine Baldini, Edouard Auclin, et al.
Plos One|May 10, 2019
Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modelingPatricia Martin-Romano, Belén P Solans, David Cano, et al.
European Journal of Cancer (Oxford, England : 1990)|April 4, 2022
Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugsEmeline Guiard, Capucine Baldini, Cédric Pobel, et al.
British Journal of Cancer|August 19, 2016
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancerPatricia Martin-Romano, Jose J Sola, Juan A Diaz-Gonzalez, et al.
Pageof 3